When two markers were determined in identical blood samples, combined sensitivity values disclosed the superiority of the combination of PAI-1 together with CATB or uPA (both markers correctly test-positive for tumor patients in 78% and 64%, respectively; one of two markers correctly test-positive in the tumor group in 98%) as compared to the combinations of all other markers, including proteases with CEA or CA 19-9, or CEA with CA 19-9. Here, CEACAM5 is linked to neoplasm.